Local Institution

Roma 78584

0 studies enrolling now · 71 studies all time

What they study most

Acute Coronary Syndrome, Acute Coronary Syndrome (ACS), Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma, Atrial Fibrillation, Atrial Flutter, Bipolar Disorder, Bladder Cancer, Bladder Neoplasms, Blast Crisis, Breast Cancer, Cancer, Cancer, Hepatocellular

Studies at this site

• Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE) — Running, not enrolling
• A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib — Completed
• A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer — Completed
• Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV — Stopped early
• An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3) — Completed
• Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) — Completed
• Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting — Completed
• Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma — Completed
• A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) — Completed
• Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) — Completed
• Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia — Completed
• Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease — Stopped early
• Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) — Completed
• An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia — Stopped early
• Effects of Abatacept in Patients With Early Rheumatoid Arthritis — Completed
• Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer — Completed
• Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia — Completed
• A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia — Completed
• Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma — Completed
• Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC — Completed
• Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab — Completed
• Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir — Completed
• Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation — Completed
• Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma — Completed
• Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant — Completed
• Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access — Completed
• A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer — Stopped early
• A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia — Completed
• Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment — Completed
• BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis — Completed
• Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib — Completed
• Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer — Completed
• First Line Hepato Cellular Carcinoma (HCC) — Completed
• Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML — Completed
• Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT) — Completed
• Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials — Completed
• An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy — Completed
• A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer — Completed
• Phase III Acute Coronary Syndrome — Stopped early
• Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia — Completed
• Safety Study of Apixaban in Recent Acute Coronary Syndrome — Completed
• Methotrexate-Inadequate Response Study — Completed
• Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer — Stopped early
• Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression — Completed
• Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C — Completed
• Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin — Completed
• Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) — Completed
• Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen — Completed
• Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis — Completed
• Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve) — Completed